Skip to main content

Table 1 Clinical trial efficacy results of novel single-agent treatments

From: Therapeutic options in peripheral T cell lymphoma

Agent

Targeting site

Phase

No. of evaluable patients

Type of patients

Outcomes

ClinicalTrial.gov ID

References

Tipifarnib

Farnesyltransferase inhibitor

II

12

PTCL

50 % ORR

NCT00082888

[49]

Darinaparsin

Organic arsenic compound

II

7

PTCL

28.6 % ORR, 3.6 months median TTF, 6.4 months OS

NCT00421213

[50]

Panobinostat

Pan-deacetylase inhibitor

II

139

CTCL

17.3 % ORR

NCT00425555

[51]

Denileukin diftitox

Interleukin fusion protein

III

263

CTCL

38 % ORR, median DoR was 277 days

NCT00050999

[52]

NCT00051012

Ixazomib

Proteasome inhibitor

I

4

PTCL

1 PR

NCT00893464

[53]

Sorafenib

Multikinase inhibitor

12

PTCL/CTCL

42 % ORR, 4 CR, 1 PR

[54]

Forodesine

PNP inhibitor

II

101

CTCL

No CR, 11 % PR, 50 % SD, median DoR was 191 days

NCT00501735

[55]

  1. ORR overall response rate, CR complete response, PR partial response, SD stable disease, TTF time to treatment failure, OS overall survival, DoR duration of response, PNP purine nucleoside phosphorylase